The overall impact of the foregoing on profitability is partially offset by savings in cost of revenues and SG&A.
Express Scripts originally estimated that adjusted EBITDA per claim (as defined in the attached Appendix) for 2011 would be in the range of $3.70 to $3.90. However, primarily as a result of the foregoing, the Company now believes that adjusted EBITDA per claim will instead likely be between $3.55 and $3.70, which represents an increase of between 11% and 16% over fiscal year 2010 reported numbers.
Express Scripts continues to expect that cash flow from operations will be between $2.2 billion and $2.4 billion for fiscal year 2011, excluding any transaction related fees and expenses due to the pending Medco merger.
In addition, due to the pending transaction with Medco, at the conclusion of the Company's previously-announced accelerated share repurchase program, the Company does not anticipate that it will engage in any further share repurchase activity until after the closing of the transaction.
About Express Scripts
Express Scripts, Inc., one of the largest pharmacy benefit management companies in North America, is leading the way toward creating better health and value for patients through Consumerology®, the advanced application of the behavioral sciences to healthcare. This approach is helping millions of members realize greater healthcare outcomes and lowering cost by assisting in influencing their behavior. Headquartered in St. Louis, Express Scripts provides integrated PBM services including network-pharmacy claims processing, home delivery services, specialty benefit management, benefit-design consultation, drug-utilization review, formulary management, and medical and drug data analysis services. The company also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services. More information c
|SOURCE Express Scripts, Inc.|
Copyright©2010 PR Newswire.
All rights reserved